Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

Abstract

Study Design

Systematic review.

Objectives

The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.

Methods

A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov.

Results

A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified.

Conclusions

There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.

Keywords

spine oncology targeted therapy chordoma chondrosarcoma malignant tumor

Introduction

Chordoma (CH) and chondrosarcoma (CHS) are rare low-grade malignant tumours (LGMTs) affecting the spine. These diseases are characterized by slow growth and late development of distant metastasis; however, they are locally aggressive, tend to recur locally and are potentially lethal due to the biological, neurological and biomechanical consequences.

Conventional chemotherapy has limited therapeutic impact in LGMTs, and the role of radiotherapy is typically in the adjuvant post-operative setting. Ultimately, the first line of treatment is surgery with an aggressive curative procedure as the goal. The main prognostic factor for local recurrence (LR) is the quality of surgical margins (i.e., wide/marginal en bloc vs intralesional resection).¹ The localisation of the primary lesion also influences the outcome of the surgical treatment. Results from a large multicentric sacral CH cohort report an odds ratio (OR) for LR of 2.43 in the case of intralesional (Enneking inappropriate, EI) resections compared to Enneking appropriate (EA) en bloc resecetions.² The same study group found that the OR for LR in the case of EI surgical treatment was 7.02 in mobile spine CH patients.³ For CHS, the LR rate in a 10 year follow-up period were 21% in EA and 48% in EI resections. However, in this large cohort, the LR risk was significantly higher in sacral CHS (45% vs 21%) which was significantly associated with disease related mortality (risk ratio = 3.6).⁴

In the real world, Enneking appropriate – en bloc – resections are simply not possible for every patient due to the anatomical localization (i.e., skull base or sacrum) and the extent of disease.^5,6 Moreover, radical, wide surgical resections can be usually associated with severe complications, loss of function and poor quality of life.^7,8 Therefore, a significant proportion of surgical resections are Enneking inappropriate. Despite aggressive surgical resections, in either case, effective adjuvant therapy would be desirable in particular when there is residual disease.

Radiotherapy (RT) requires a high dose approach (more than 70 Gy) for both CHS and CH as conventional dosing does not yield long term local control. In particular for CH, it has been shown that a total dose less than 60 Gy given in conventional fractionation is associated with poor local control. Therefore, practice typically varies from 70 to 78 Gy, with a recommendation of at least 74 Gy with photon or protons. Dosing can vary if carbon ion therapy applied.⁹ For CHS, typical radiotherapy practice is to treat adjuvantly in the range of 70 Gy in 35 fractions. The higher radiation doses required for CH are not required for CHS as it is more sensitive to the effects of radiation.¹⁰ As a result, if the en bloc Enneking-appropriate surgical resection would result in unacceptable functional loss, or tumour-free surgical margins are not achieved, long term local control can be expected after effective radiation. The application of stereotactic body radiotherapy for LGMTs is in evolution with early encouraging results.¹¹

Chemotherapy has long been known to be ineffective in CH, reports of tumour response to chemotherapy (cisplatin, anthracyclines) have been anecdotal. Therefore, chemotherapy has played a limited role in the management of CH.¹ Adjuvant chemotherapy may provide some survival advantage in dedifferentiated and mesenchymal CHS, but there is little evidence supporting the effectiveness in the conventional CHS subset.¹² In a single institution study of 42 patients, conventional chemotherapy provided no benefit in disease-free survival for conventional CHS.¹³ Chemotherapy resistance in CHS may be linked to the expression of multidrug resistance 1 gene (MDR-1). Moreover, the access of chemotherapeutic substances may be hindered by poor vascularity of the tumour and large amount of extracellular matrix, implying that the drugs have to diffuse relatively long distances to the tumour cells.¹⁴

Low-grade malignant tumours are challenging to treat with conventional oncological treatment modalities (limited effectiveness of RT and chemotherapy), thus recent research and development projects aim to find new therapeutic methods targeting molecular pathways. In the previous decade, treatment of other malignancies like non-small cell lung cancer (NSCLC) has evolved to a great extent with the discovery of oncogenic driver mutations allowing for patient specific targeted treatment. For example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors provide a favourable treatment outcome in EGFR mutation positive lung cancers.¹⁵ In melanoma, 5-year survival rates greatly increased compared to 10 years ago from <5% to around 30% secondary to the advancements in targeted molecular and immunotherapy.¹⁶

This review summarizes the current state of targeted molecular and immunotherapies as well as other novel systemic therapeutic options for CH and CHS.

Methods and Search Results

Search Strategies

Electronic searches were performed by March 10th, 2023 using PubMed, MEDLINE and Cochrane libraries. All searches and selection were performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and recommendations.¹⁷ The search strategies can be found in Supplement 1. We included studies detailing other tumour types if either CH or CHS were among them. We also performed a search on clinicaltrials.gov to find and list all ongoing clinical trials and actively recruiting clinical trials. Informed consent and institutional review board approval were not required due to the nature of the study.

Selection Criteria

Selection criteria included the following: ongoing and finished clinical trials for patients with CH and CHS at any anatomic location along the spine, we also included studies with other type of tumours as long as at least one patient with CH or CHS was included in the paper; in patients over the age of 18 undergoing treatment with at least one agent with or without other kind of therapies. Case reports were also taken in consideration as long as the above-mentioned criteria were met. Previous reviews in this subject were also included in the systematic review. Animal models and in vitro studies, studies with not specified agents, studies of non-spinal CHS or CH were excluded from the selection. All articles were screened in accordance with the selection criteria by three independent investigators. Any discrepancies were resolved through discussion until consensus was reached if no consensus was reached the senior investigator made the final decision.

Search Results

The initial search resulted 311 studies. After duplications were removed 269 article abstracts were screened. We excluded 73 articles based on their abstracts, then we thoroughly screened 196 full-text papers for potential inclusion. Animal and in vitro studies, studies with insufficient data (i.e., no drug type), studies without targeted therapy were excluded, resulting in 73 papers included in this review (3 case report, 3 case series, 21 clinical trial, 24 original article, 22 review). We also identified 20 actively recruiting ongoing clinical trials (12 for CHS, 8 for CH) from clinicaltrials.gov.

Possible Molecular Targets

Chordoma

PDGF and PDGFR Pathway

Platelet derived growth factors (PDGF) and platelet derived growth factor receptors (PDGFR) are a family of receptors and hormones that have been shown to influence the growth and invasion of numerous tumours, through modification of stem cell recruitment, angiogenesis, and modification of tumour microenvironment.¹⁸ PDGF and PDGFR has been shown to be expressed in CH, and their overexpression is associated with worse overall outcomes and a more aggressive phenotype.¹⁹

There are therapeutic agents such as the tyrosine kinase inhibitor imatinib mesylate target PDGF. Numerous clinical trials^20-22 and case presentations^23-25 have assessed the effectiveness of imatinib in CH patients. A modest clinical response was shown in 7 imatinib treated chordoma patients with long lasting stable disease and a median progression free survival (PFS) of 10 months (range: 4.2-18+ months).²¹ Severe adverse events developed in a significant number of patients, therefore, the treatment was suspended in 7 cases of 26 patients.²¹ Dose reduction were needed in 4 cases (28%) which also highlight the potential toxicity of this therapy in this population.²¹ Stacchiotti et al reported on imatinib combined with everolimus (an mTOR inhibitor, see later) yielding a median PFS of 14 months. This result suggests that targeting more than one pathway can increase the treatment efficacy for CH.²⁰

VEGFR Pathway

Vascular endothelial growth factor receptor (VEGFR) physiologically plays a role in developing and sustaining angiogenesis. Tumour growth is often correlated with the level of VEGFR-induced neoangiogenesis.²⁶ A review concluded that VEGF inhibiting molecules modulate the tumour immune suppressive microenvironment by enhancing T-cell response.²⁷ Genetic profiling of CH has revealed that CH overexpresses VEGFR such that it vividly stained positive in more than 80% of CH samples.^26,28

Sorafenib, another tyrosine kinase inhibitor, has profound effect on VEGFR.²⁹ A clinical trial reported a 12 month PFS rate of 73% in CH patients,²⁹ furthermore, PFS was correlated with the level of circulating VEGFR.²⁹ Sunitinib was also used to treat a patient with a clival CH as reported in a case report. According to the Response Evaluation Criteria in Solid Tumours (RECIST), the patient had 24 months of stable disease (SD).²³ Sunitinib also has activity against PDGFR, FLT3, KIT, CSF-1 and RET.

In a trial published in 2020, VEGFR inhibitor apatinib was used to treat CH patients with a promising PFS rate of 18 months.³⁰

EGFR Pathway

Epidermal growth factor receptors (EGFR) maintain and regulate the epithelium. EGFR activation by mutation and amplification has been shown to increase growth and resistance to various drugs in different tumours.³¹ CH is known to be immune reactive to activated EGFR but does not harbour mutations in EGFR. Several agents have been used in CH targeting EGFR.³² Lapatinib has shown a clinical benefit rate of 22% (complete response (CR) + partial response (PR) + SD ≥ 6 months).³³ A retrospective study assessed the responsiveness to various off label used agents in CH patients, and found a PFS of 15 months with erlotinib.³⁴ An attempt at trying to define the activity of cetuximab, a monoclonal antibody against EGFR is ongoing.

mTOR Pathway

The mTOR pathway is involved in cell growth, cytoskeletal reorganization and proliferation.³⁵ Pathological activation of mTOR promotes tumour resistance to chemotherapeutic agents. A study estimated that CH may be responsive to mTOR inhibitor rapamycin/sirolimus based on the 65% of incidence of mTOR positivity in CH.³⁶ mTOR inhibitors as monotherapy showed little efficacy, but combinations of everolimus plus imatinib and imatinib plus sirolimus showed promise.³⁷ In a single case presentation, a patient treated with imatinib combined with the mTOR inhibitor everolimus showed stable disease for 16 months. In another study imatinib combined with everolimus, amongst 9 CH patients one achieved a PR, 7 SD, and one progressive disease (PD) at 3 months. The overall clinical benefit rate (RECIST CR + PR + SD ≥ 6 months) was 89%.³⁸

Nuclear Export Pathway

The tumour surveillance functions of most tumour suppressor proteins are dependent on their location within the cell nucleus. In most neoplastic cells, increased nuclear export results in the inactivation of tumour suppressor proteins. Exportin 1 mediates the nuclear export of numerous mammalian cargo proteins. Exportin 1 is overexpressed in most cancerous cells and is typically correlated with poor prognosis in pancreatic, ovarian, and cervical cancers. Inhibition of exportin 1 is expected to result in activation of tumour suppressor proteins.^39-41 Selinexor is a highly specific inhibitor of exportin 1, which showed promising results in solid tumours in a completed trial (NCT01607905); however, the only one recruited CH patient did not show response to the treatment.³⁹

Chondrosarcoma

“Classical” Molecular Targeted Therapies

Several different histologic CHS subtypes have been identified through novel signalling pathways, which encouraged investigation into the therapeutic efficacy of inhibitors of the commonly activated receptor tyrosine kinases.⁴² Conventional CHS is characterized by over expression and/or activation of PDGFR, however, the tyrosine kinase inhibitor imatinib was of no clinical benefit in 26 patients with metastatic advanced CHS.⁴³ Moreover, dasatinib (another PDGFR inhibitor) was ineffective in 31 patients in another study.⁴⁴

A combination of sirolimus (mTOR inhibitor) and cyclophosphamide showed modest clinical activity in 10 patients. In that study, one objective response was observed, 6 had SD for at least 6 months, and 3 had PD. The median PFS was 13.4 months.⁴⁵ Selective mTOR inhibitors such as the “classical” molecular targeted therapeutic agent sirolimus can promote drug resistance through suppressing negative feedback loops that oppose their antiproliferative effect by overactivating Akt phosphorylation.⁴⁵

A phase II clinical trial with pazopanib, an anti-VEGFR tyrosine kinase inhibitor was conducted in 26 patients with extraskeletal myxoid CHS (EMC). EMC is extremely rare subtype of CHS; it is marked by a specific translocation with the gene NR4A3.⁴⁶ 22 patients were evaluable for analysis at the primary endpoint. Four patients had a RECIST objective response. They concluded that pazopanib had a clinically meaningful antitumour activity in patients with advanced and progressive EMC, and could be a second line treatment option if the anthracycline-based first line chemotherapy fails (NCT02066285).⁴⁶

HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors cause hyperacetylation of histones which leads to gene transcription and inhibits cell proliferation, invasion, formation of metastases and neoangiogenesis.⁴⁷ HDAC inhibitor treatment induces apoptosis, cell cycle arrest and differentiation in numerous tumour cells including CHS.⁴⁷ There was a phase II clinical trial involving romidepsin a HDAC inhibitor used on 40 CHS patients. The trial ended in 2017, only one patient finished the trial, the median PFS was 1.9 months, and the median survival was 12.2 months. There was no patient with complete response.⁴⁸

IDH Mutations

Isocitrate dehydrogenase (IDH) is an enzyme that helps in the conversion of isocitrate to α-ketoglutarate. IDH1 is localized in the cytoplasm, IDH2 and 3 act in the mitochondria. Mutation on IDH1 and 2 can lead to gain-of-function by which these enzymes can convert α-ketoglutarate to oncometabolite D-2-hydroxyglutarate leading to DNA hypomethylation.⁴⁹ IDH1 and 2 mutations are early events in different tumourigenesis.⁴⁹ Around 54% of CHS contain mutations in IDH1 or IDH2.⁴⁹ These mutations elevate oncometabolites (D-2-hydroxyglutarate, 2-HG), leading to DNA hypermethylation.⁴⁹ Ivosidenib, a mutant IDH1 inhibitor, in a phase I clinical study showed proof of clinical activity, tolerability and significant reduction of the 2-HG (by up to 98%) in plasma and in the tumour in 21 patients with advanced CHS.⁵⁰ Clinical trials evaluating response rates and PFS in patients with CHS are ongoing.

Hedgehog Signalling Pathway

The Hedgehog signalling pathway plays a crucial role in many developmental processes such as pattern formation, proliferation, differentiation, and apoptosis.⁵¹ In a phase II clinical trial hedgehog pathway inhibitor saridegib was used on patients with metastatic or locally advanced CHS, the trial was discontinued early after the analysis of available data showed that saridegib was not superior to placebo.⁴²

Src Family Pathway

The Src kinase family is a family of non-receptor tyrosine kinases. It interacts with cytosolic, nuclear and membrane proteins. Dysregulation of the Src family contributes to progression of cellular transformation, and oncogenic activity. In CHS, the Src pathway seems to be active and inhibition by dasatinib has led to reduced CHS viability in in vitro studies.⁴⁴ Unfortunately, in a phase II clinical trial, dasatinib failed to achieve local control for at least 6 months in more than 50% of the patients, thus proved ineffective in CHS (NCT00464620).⁴⁴

RET Pathway

Rearranged during transfection (RET) gene is a proven proto-oncogene. Genomic alterations involving RET are oncogenic drivers of numerous tumours.⁵² RXDX-105 is a VEGFR sparing multikinase inhibitor with activity against RET. In a phase I/Ib clinical trial, it was shown that adverse event profile of RXDX-105 appears manageable, and showed preliminary efficacy in patients with RET alterations in CHS (NCT01877811).⁵³

Other Agents

Currently there are numerous chemotherapeutic agents, herbal agents, molecular targets, pathways that are under excessive research in the treatment of chemotherapy resistant CHS.⁴² Most of these substances are in the in vitro or in animal model in vivo stage and promising human results are lacking.⁴²

Ongoing Clinical Trials

In this report we listed the ongoing clinical trials targeting the different molecular pathways. The actively recruiting clinical trials are also represented on Table 1.

Table 1.

Ongoing Clinical Trials Open for Recruitment in Chordoma (A) and Chondrosarcoma (B).

Study Title	Phase	Registration Number	Drug	Pathway	Tumour	Contacts and Location Link
A
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)	3	NCT04741438	Nivolumab + Ipilimumab	PD-L1, CTLA-4	Chordoma	https://clinicaltrials.gov/ct2/show/NCT04741438#contacts
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer	1	NCT04246671	TAEK-VAC-HerBy Vaccine	Brachyury	Chordoma	https://clinicaltrials.gov/ct2/show/NCT04246671?recrs=ab&cond=chordoma&draw=2&rank=10#contacts
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc)	2	NCT03242382	Palbociclib	CDK4/6	Chordoma	https://clinicaltrials.gov/ct2/show/NCT03242382?recrs=ab&cond=chordoma&draw=2&rank=11#contacts
Tazemetostat + Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors	2	NCT05407441	Tazemetostat,	EZH2, PD-L1, CTLA-4	Chordoma	https://clinicaltrials.gov/ct2/show/NCT05407441?recrs=ab&cond=chordoma&draw=2&rank=14#contacts
			Nivolumab,
			Ipilimumab
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers	2	NCT04416568	Nivolumab, Ipilimumab	PD-L1, CLTA-4	Chordoma	https://clinicaltrials.gov/ct2/show/NCT04416568?recrs=ab&cond=chordoma&draw=2&rank=15#contacts
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	2	NCT05286801	Tiragolumab, Atezolizumab	anti-TIGIT antibody, PD-L1	Chordoma	https://clinicaltrials.gov/ct2/show/NCT05286801?recrs=ab&cond=chordoma&draw=2&rank=16#contacts
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors	1	NCT04965753	FHD-609	BRD9	Chordoma	https://clinicaltrials.gov/ct2/show/NCT04965753?recrs=ab&cond=chordoma&draw=2&rank=19#contacts
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma	2	NCT05041127	Cetuximab	EGFR	Chordoma	https://classic.clinicaltrials.gov/ct2/show/NCT05041127#contacts
B
Study of INBRX-109 in Conventional Chondrosarcoma	2	NCT04950075	INBRX-109	Death receptor 5	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT04950075#contacts
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE)	2	NCT02389244	Regorafenib	VEGFR2	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT02389244?term=NCT02389244&draw=2&rank=1#contacts
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma	2	NCT05193188	Anlotinib ± PD-1 Antibody	VEGFR2/3, PD-1	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT05193188#contacts
AG-120 in People With IDH1 Mutant Chondrosarcoma	2	NCT04278781	AG-120	IDH1	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT04278781?recrs=ab&cond=chondrosarcoma&draw=2&rank=4#contacts
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration	2	NCT04040205	Abemaciclib	CDK4/6	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT04040205?recrs=ab&cond=chondrosarcoma&draw=2&rank=7#contacts
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	1	NCT05039801	IACS-6274 ±Bevacizumab + Paclitaxel	GLS1	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT05039801?recrs=ab&cond=chondrosarcoma&draw=3&rank=20#contacts
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas	1	NCT03670069	Itacitinib	JAK1	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT03670069?recrs=ab&cond=chondrosarcoma&draw=3&rank=23#contacts
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	1	NCT03600649	Seclidemstat	LSD1	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT03600649?recrs=ab&cond=chondrosarcoma&draw=3&rank=24#contacts
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations	1	NCT04762602	HMPL-306	mIDH1, mIDH2	Chondrosacroma	https://clinicaltrials.gov/ct2/show/NCT04762602?recrs=ab&cond=chondrosarcoma&draw=3&rank=25#contacts
Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS)	2	NCT05131386	Trabectedin	transcription factor FUS-CHOP	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT05131386?recrs=ab&cond=chondrosarcoma&draw=3&rank=26#contacts
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc)	2	NCT03277924	Sunitinib ± Nivolumab+Chemotherapy	PDGFR, VEGFR, PD-L1	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT03277924?recrs=ab&cond=chondrosarcoma&draw=3&rank=27#contacts
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	1	NCT04521686	LY3410738	IDH1, IDH2	Chondrosarcoma	https://clinicaltrials.gov/ct2/show/NCT04521686?recrs=ab&cond=chondrosarcoma&draw=2&rank=8#contacts

Chordoma

Brachyury

Brachyury is an oncogene transcription factor of the T-box gene family, with high expression in many malignancies (i.e.,: chordoma). It facilitates tumour resistance to chemotherapy and radiotherapy, contributes to proliferation.⁵⁴ During the embryogenesis, brachyury regulates mesodermal differentiation to notochord, and maintains stem cells during the development of neural axis.⁵⁵ CH in almost all cases overexpress brachyury, however its role of the level of overexpression in the prognosis has not been fully elucidated.^56,57

There have been a few trials with brachyury expression targeting vaccination. One trial, focusing on the which was a combination of different acting agents was withdrawn before the first patient enrolment (NCT03647423, withdrawn). Clinical trial with GI-6301 yeast-brachyury vaccine was in phase II (NCT02383498, discontinued), however due to ineffectiveness the trial was discontinued early.⁵⁸

There is an ongoing clinical trial with afatinib, an EGFR inhibitor which has some effect on brachyury (NCT03083678, active not recruiting).

Growth Factors Pathways Targeting Trials

Multiple kinases are under clinical trials targeting VEGFR, PDGF or PDGFR and EGFR pathways. Regorafenib a multi-kinase inhibitor proved to be safe to use in patients with CH and CHS. In a phase II clinical trial (NCT02389244, active recruiting) 46 patients were involved from 2014 to 2019. Forty patients were evaluated for efficacy, 24 on regorafenib and 16 on placebo. It showed promising result with a median PFS at 19.9 weeks vs 8 weeks in the placebo cohort. Moreover at 12 weeks, 13 patients were non-progressive vs 5 in the placebo cohort (Figure 1). The trial is scheduled to finish in 2025.⁵⁹

Figure 1.

Regorafenib in recurrent thoracic chondrosarcoma. T2 weighted MRI of a 79 year old male patient with a 6-year long history of thoracic chondrosarcoma. A large recurrent tumour at ThVI-VII (A) was surgically treated with a partial, intralesional resection (B), but the Grade II chondrosarcoma developed a fastly growing local recurrence in 3 months (C). Regorafenib treatment was initiated and showed stable disease status at 3-month FU (D).

Anlotinib is another multi-kinase inhibitor with activity against VEGFR, PDGFR and c-kit. Its efficacy vs placebo was previously proven in soft tissue neoplasms such as NSCLC, renal cell carcinoma, and medullary thyroid carcinoma.⁶⁰ There is an ongoing phase II clinical trial in locally advanced, unresectable or metastatic CH with anlotinib with no reported results yet (NCT04042597, unknown status).

A phase II clinical trial (NCT 00874874, unknown status) showed promising results with a new tyrosine kinase inhibitor, sorafenib, in CH. The 9-month PFS was 91.7% with sorafenib (n = 27), however there was no association between the change in VEGFR and the PFS.

Cetuximab an EGFR inhibitor monoclonal antibody is under investigation in a phase II clinical trial in unresectable or metastatic CH patients (NCT05041127, active recruiting).

CDK4/6 Pathway

Cyclin-dependent kinases (CDK) play important role in sarcoma cell cycle. CDK4 is a key regulator of G1 phase progression and G1-S transition. CDK4 with cyclin D1 forms a complex and phosphorylates retinoblastoma (Rb) protein and inactivates its function. This causes cell cycle progression by relieving the Rb mediated inhibition of transcription factor E2F. Studies have discovered activation of CDK4/6 pathway in CH due to deletion of p16 tumour suppressor gene. P16 is one of the most frequently mutated tumour suppressor gene, it has a pivotal role in the transition of G1 to S phase of cell cycle.^61,62 There is an ongoing phase II clinical trial (NCT03110744, completed) with CDK4/6 inhibitor palbociclib on locally advanced/metastatic CH. Where the median PFS of 5.75 months (n = 26) and overall survival rate of 74% at 2 years was observed.⁶³

PD-1, PDL-1 Pathway

Programmed death 1 (PD-1) and its ligands are expressed on the surface of tumours and lymphocytes. PD-1 and its ligands role have been studied in tumour progression. Currently the interaction between the host immune system and the tumour is poorly understood. Studies have shown that CH cells demonstrate inducible PD-1 expression which can be targeted by drugs.⁶⁴ Nivolumab binds to the PD-1 receptor and blocks its interaction with its ligands, thus prevents PD-1 pathway from inhibition the immune response. Based on this molecular interaction, a few clinical trials with nivolumab on chordoma have been launched (NCT02989636 active not recruiting, NCT03623854 active not recruiting, NCT03886311 active recruiting, NCT04416568 active recruiting),^65-68 but there have not been any results reported yet.

Chondrosarcoma

CHS seems to be more resistant to conventional targeted therapies than CH. There are a lot of new therapies in development mostly in in vitro phase. Beside a few ongoing clinical trials there are some previously promising ways which have proved to be ineffective recently.⁴²

Immunotherapy

Nivolumab and pembrolizumab (both anti-programmed death 1 (PD-1) antibodies have recorded objective response in 2 patients with dedifferentiated CHS.^69,70 These results are encouraging to patients with CHS, however severe/lethal neurologic immune-related adverse events have been associated with immune checkpoint inhibitors, including those targeting PD-1.⁷¹

Vascular Endothelial Growth Factor Receptor

Anlotinib a novel tyrosine kinase inhibitor acting on VEGFR combined with PD-1 antibody is under a phase II clinical trial recruiting unresectable, high-grade CHS patients. The trial started in early 2023 (NCT05193188, active recruiting).⁷² REGOBONE trial is a randomized, placebo-controlled, multicentric, phase II study in France about the effect of regorafenib in locally advanced or metastatic bone sarcomas including CHS and CH as well showing promising results (see above and Figure 1) (NCT02389244, active recruiting).

Heterogeneous Nuclear Ribonucleoprotein P2

Heterogeneous nuclear ribonucleoprotein P2 is also known as RNA-binding protein FUS/TLS (FUsed in Sarcoma/Translocated in LipoSarcoma). FUS gene rearrangement has been implicated in the pathogenesis of wide range of malignant and benign tumours.⁷³ Trabectedin is reported to be effective against translocation related sarcomas. In a phase II clinical trial, 5 patients with translocation related CHS (extraskeletal myxoid, and mesenchymal) were treated with trabectedin (JapicCTI-121850, no information/Japanese/completed). The sub-analysis showed a median PFS of 12.5 months and an overall survival of 26.4 months. One patient showed partial response the others showed stable disease.⁷⁴

Death Receptor 5

Death receptor 5 (DR5) is a member of the tumour necrosis factor (TNF) receptor superfamily. It binds TNF-related apoptosis-inducing ligand (TRAIL) and meditates apoptosis. INBRX-109 is a tetravalent DR5 agonist antibody that exploits the tumour specific cell death induced by DR5 activation. In a phase 1 dose escalation study, 20 patients with conventional CHS were enrolled. Two of them achieved partial response, 14 subjects had stable disease, and the disease control rate was 89%.⁷⁵ Currently the phase II study is actively enrolling (NCT04950075). ⁷⁶

IDH1 Inhibitors

A phase II clinical trial investigating ivosidenib is actively recruiting CHS patient with IDH1 mutations (NCT04278781).

CDK4/6 Pathway

Patients are recruited to a single-arm, phase II study about the effect of abemaciclib (CDK4/6 inhibitor) on CHS (NCT04040205).

Conclusion

CH and CHS are different histologically, yet they share common attributes which makes them difficult to treat and achieve good local control. Although these low-grade malignant pathologies are slow growing, they are locally aggressive and ultimately cause death if not controlled. They tend to recur after initial treatment, even in the case of Enneking appropriate surgical resection, and appropriate consultation with radiation and medical oncology should be performed up-front in all patients as multidisciplinary discussions are critical to proper care.

In the past decades, several molecular pathways have emerged as potential targets to achieve better clinical outcomes. CH has more potential molecular therapeutic targets, and various tyrosine kinase inhibitors (e.g.,: imatinib-PDGFR, sunitinib-VEGFR, lapatinib-EGFR) have shown moderate to good PFS rates. One has to be cautious in interpreting the data as sample sizes are limited and toxicity profiles can be disadvantageous. Unfortunately, these drugs have yet to demonstrate significant clinical activity in CHS.⁴² More molecular pathway targets are under intense research in the treatment of CHS; however, most are in in vitro or in animal model stages.

At present, in the patient presenting with a low grade malignant spinal tumour, there is no pharmaceutical treatment alternative for the Enneking appropriate surgical resection. Some recent and ongoing clinical trials with targeted molecular therapy show better oncological response compared to conventional options, and can be used to treat patients with recurrent or metastatic disease.

Supplemental Material

Supplemental Material - Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

Supplemental Material for Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma by Adam Biczo, Arjun Sahgal, Jorrit-Jan Verlaan, Patel Shreyaskumar, Zsolt Szoverfi, Markus Schultheiss, Laurence Rhines, Jeremy Reynolds, Ilya Laufer, Alessandro Gasbarrini, Nicolas Dea, Ziya Gokaslan, Charles Fisher, Chetan Bettegowda, Stefano Boriani, Francis Hornicek, Rory Goodwin, and Aron Lazary in Global Spine Journal

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was organized and funded by AO Spine through the AO Spine Knowledge Forum Tumor, a focused group of international Tumor experts. AO Spine is a clinical division of the AO Foundation, which is an independent medically-guided not-for-profit organization.

ORCID iDs

Adam Biczo

Rory Goodwin

Aron Lazary

Supplemental Material

Supplemental material for this article is available online.

References

Casali

Stacchiotti

Sangalli

Olmi

Gronchi

. Chordoma. Published online 2007.

Varga

Szövérfi

Fisher

, et al. Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J. 2015;24(5):1092-1101. doi:10.1007/S00586-014-3728-6

Gokaslan

Zadnik

Sciubba

, et al. Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database. J Neurosurg Spine. 2016;24(4):644-651. doi:10.3171/2015.7.SPINE15201

Fisher

Versteeg

Dea

, et al. Surgical management of spinal chondrosarcomas. Spine. 2016;41(8):678-685. doi:10.1097/BRS.0000000000001485

Ulici

Hart

. Chordoma. Arch Pathol Lab Med. 2022;146(3):386-395. doi:10.5858/arpa.2020-0258-RA

Boriani

Saravanja

Yamada

Varga

Biagini

Fisher

. Challenges of local recurrence and cure in low grade malignant tumors of the spine. Spine (Phila Pa 1976). 2009;34(22 Suppl):S48-S57. doi:10.1097/brs.0b013e3181b969ac

Charest-Morin

Dea

Fisher

. Health-related quality of life after spine surgery for primary bone tumour. Curr Treat Options Oncol. 2016;17(2):9-12. doi:10.1007/S11864-015-0383-Z

Chen

Yang

Kandimalla

Liu

Jyong

Wang

. Review of current treatment of sacral chordoma. Orthop Surg. 2009;1(3):238-244. doi:10.1111/j.1757-7861.2009.00027.x

Stacchiotti

Sommer

Chordoma Global Consensus Group . Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16(2):e71-e83. doi:10.1016/S1470-2045(14)71190-8

10.

Sahgal

Chan

Atenafu

, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. Neuro Oncol. 2015;17(6):889-894. doi:10.1093/NEUONC/NOU347

11.

Jin

Berry-Candelario

Reiner

, et al. Long-term outcomes of high-dose single-fraction radiosurgery for chordomas of the spine and sacrum. J Neurosurg Spine. 2020;32(1):79-88. doi:10.3171/2019.7.SPINE19515

12.

Whelan

Davis

. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36(2):188-193. doi:10.1200/JCO.2017.75.1743

13.

Rock

Ali

Chow

. Systemic therapy for chondrosarcoma. Curr Treat Options Oncol. 2022;23(2):199-209. doi:10.1007/S11864-022-00951-7/TABLES/1

14.

Gelderblom

Hogendoorn

PCW

Dijkstra

, et al. The clinical approach towards chondrosarcoma. Oncol. 2008;13:320-329. doi:10.1634/theoncologist.2007-0237

15.

Shih

. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. doi:10.1186/S12943-018-0777-1

16.

Guo

Wang

. Signal pathways of melanoma and targeted therapy. Signal Transduct Targeted Ther. 2021;6(1):424. doi:10.1038/S41392-021-00827-6

17.

Moher

Liberati

Tetzlaff

Altman

PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012. doi:10.1016/j.jclinepi.2009.06.005

18.

Akinduro

Suarez-Meade

Garcia

, et al. Targeted therapy for chordoma: key molecular signaling pathways and the role of multimodal therapy. Target Oncol. 2021;16(3):325-337. doi:10.1007/s11523-021-00814-5

19.

Zhai

Bai

Wang

, et al. Differences in dural penetration of clival chordomas are associated with different prognosis and expression of platelet-derived growth factor receptor-β. World Neurosurg. 2017;98:288-295. doi:10.1016/j.wneu.2016.07.096

20.

Stacchiotti

Morosi

Lo Vullo

, et al. Imatinib and everolimus in patients with progressing advanced chordoma: a phase 2 clinical study. Cancer. 2018;124(20):4056-4063. doi:10.1002/cncr.31685

21.

Adenis

Ray-Coquard

Italiano

, et al. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. Br J Cancer. 2013;109(10):2574-2578. doi:10.1038/bjc.2013.648

22.

Stacchiotti

Longhi

Ferraresi

, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30(9):914-920. doi:10.1200/JCO.2011.35.3656

23.

Alan

Akin Telli

Ercelep

, et al. Chordoma: a case series and review of the literature. J Med Case Rep. 2018;12(1):239. doi:10.1186/s13256-018-1784-y

24.

Ferraresi

Nuzzo

Zoccali

, et al. Chordoma clinical characteristicsmanagement.Pdf. Published online 2010.

25.

Hindi

Casali

Morosi

, et al. Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer. 2015;51(17):2609-2614. doi:10.1016/j.ejca.2015.07.038

26.

Chen

Yang

, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neuro Oncol. 2011;101(3):357-363. doi:10.1007/s11060-010-0263-0

27.

Lapeyre-Prost

Terme

Pernot

, et al. Immunomodulatory Activity of VEGF in Cancer. Vol. 330. 1st ed. Amsterdam: Elsevier Inc.; 2017. doi:10.1016/bs.ircmb.2016.09.007

28.

Tauziède-Espariat

Bresson

Polivka

, et al. Prognostic and therapeutic markers in chordomas: a study of 287 tumors. J Neuropathol Exp Neurol. 2016;75(2):111-120. doi:10.1093/jnen/nlv010

29.

Bompas

Le Cesne

Tresch-Bruneel

, et al. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol. 2015;26(10):2168-2173. doi:10.1093/annonc/mdv300

30.

Liu

Jia

Wei

, et al. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2020;21(9):1244-1252. doi:10.1016/S1470-2045(20)30466-6

31.

Sigismund

Avanzato

Lanzetti

. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20. doi:10.1002/1878-0261.12155

32.

Scheipl

Barnard

Cottone

, et al. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016;239(3):320-334. doi:10.1002/path.4729

33.

Raskin

Bornhorst

. Biological treatments of neurofibromatosis type 2 and other skull base disorders. Otolaryngol Clin North Am. 2021;54(4):789-801. doi:10.1016/j.otc.2021.05.004

34.

Lebellec

Chauffert

Blay

, et al. Advanced chordoma treated by first-line molecular targeted therapies: outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d’Expression Française (ANOCEF). Eur J Cancer. 2017;79(January):119-128. doi:10.1016/j.ejca.2017.03.037

35.

Polivka

Janku

. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142(2):164-175. doi:10.1016/j.pharmthera.2013.12.004

36.

Presneau

Shalaby

Idowu

, et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009;100(9):1406-1414. doi:10.1038/sj.bjc.6605019

37.

Trapani

Conforti

De Pas

. EGFR inhibition in a pretreated sacral chordoma: a role for erlotinib? Case report and a brief review of literature. Transl Med UniSa. 2017;16(5):30-33. https://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5536160

38.

Stacchiotti

Marrari

Tamborini

, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20(11):1886-1894. doi:10.1093/ANNONC/MDP210

39.

Abdul Razak

Mau-Soerensen

Gabrail

, et al. First-in-Class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142-4150. doi:10.1200/JCO.2015.65.3949

40.

Turner

Dawson

Sullivan

. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1021-1032. doi:10.1016/J.BCP.2011.12.016

41.

Huang

Yue

Qiu

Wang

Zhou

Sun

Yjue

. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009;32(6):E315.

42.

MacDonald

Lin

Kuo

Tang

. An update on current and future treatment options for chondrosarcoma. Expert Rev Anticancer Ther. 2019;19(9):773-786. doi:10.1080/14737140.2019.1659731

43.

Grignani

Palmerini

Stacchiotti

, et al. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: an Italian Sarcoma Group study. Cancer. 2011;117(4):826-831. doi:10.1002/cncr.25632

44.

Schuetze

Bolejack

Choy

, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123(1):90-97. doi:10.1002/cncr.30379

45.

Bernstein-Molho

Kollender

Issakov

, et al. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother Pharmacol. 2012;70(6):855-860. doi:10.1007/s00280-012-1968-x

46.

Stacchiotti

Ferrari

Redondo

, et al. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(9):1252-1262. doi:10.1016/S1470-2045(19)30319-5

47.

Zhu

Tao

. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation. https://www.jbuon.com. Accessed April 14, 2023.

48.

Romidepsin

. Treating patients with metastatic or unresectable soft tissue sarcoma - tabular view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT00112463?term=NCT00112463&draw=2&rank=1. Accessed April 14, 2023.

49.

Suijker

Oosting

Koornneef

, et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 2015;6(14):12505-12519. doi:10.18632/oncotarget.3723

50.

Fan

Dai

DiNardo

, et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Cancer Chemother Pharmacol. 2020;85(5):959-968. doi:10.1007/s00280-020-04064-6

51.

Sun

Guo

Ren

, et al. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis. 2014;5(1):e979. doi:10.1038/cddis.2013.497

52.

Drilon

Patel

, et al. A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105. Cancer Discov. 2019;9(3):384-395. doi:10.1158/2159-8290.CD-18-0839

53.

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors | Cochrane Library. Accessed April 14, 2023. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01364843/full

54.

Song

Gobe

. Understanding molecular pathways and targets of brachyury in epithelial-mesenchymal transition (EMT) in human cancers. Curr Cancer Drug Targets. 2016;16(7):586-593. doi:10.2174/1568009616666160328113338

55.

Miettinen

Wang

Lasota

Heery

Schlom

Palena

. Nuclear brachyury expression is consistent in chordoma, common in germ cell tumors and small cell carcinomas, and rare in other carcinomas and sarcomas: an immunohistochemical study of 5229 cases. Am J Surg Pathol. 2015;39(10):1305-1312. doi:10.1097/PAS.0000000000000462

56.

Vujovic

Henderson

Presneau

, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209(2):157-165. doi:10.1002/PATH.1969

57.

Bettegowda

Yip

SFL

, et al. Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. Neuro Oncol. 2017;19(3):405-413. doi:10.1093/NEUONC/NOW156

58.

DeMaria

Bilusic

Park

, et al. Randomized, double-blind, placebo-controlled phase II study of yeast-brachyury vaccine (GI-6301) in combination with standard-of-care radiotherapy in locally advanced, unresectable chordoma. Unresectable Chordoma. Oncologist. 2021;26(5):e847-e858. doi:10.1002/onco.13720

59.

Duffaud

Italiano

Bompas

, et al. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Eur J Cancer. 2021;150:108-118. doi:10.1016/J.EJCA.2021.03.039

60.

Shen

Zheng

Ren

, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/S13045-018-0664-7/TABLES/3

61.

Liu

Zhang

Wang

. Clinicopathological significance of p16, cyclin D1, Rb and MIB-1 levels in skull base chordoma and chondrosarcoma. World J Otorhinolaryngol Head Neck Surg. 2015;1(1):50-56. doi:10.1016/J.WJORL.2015.09.005

62.

Liu

Shen

Choy

, et al. CDK4 expression in chordoma: a potential therapeutic target. J Orthop Res. 2018;36(6):1581-1589. doi:10.1002/JOR.23819

63.

ESMO congress | OncologyPRO. Accessed April 13, 2023. https://oncologypro.esmo.org/meeting-resources/esmo-congress/cdk4-6-inhibition-in-locally-advanced-metastatic-chordoma-nct-pmo-1601

64.

Mathios

Ruzevick

Jackson

, et al. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neuro Oncol. 2015;121(2):251-259. doi:10.1007/S11060-014-1637-5

65.

Nivolumab with or without stereotactic radiosurgery in treating patients with recurrent, advanced, or metastatic chordoma - tabular view - ClinicalTrials.gov. Accessed April 13, 2023. https://clinicaltrials.gov/ct2/show/record/NCT02989636?term=NCT02989636&draw=2&rank=1

66.

Nivolumab and relatlimab in treating participants with advanced chordoma - full text view - ClinicalTrials.gov. Accessed April 13, 2023. https://clinicaltrials.gov/ct2/show/NCT03623854?term=NCT03623854&draw=2&rank=1

67.

Talimogene laherparepvec, nivolumab and trabectedin for sarcoma - full text view - ClinicalTrials.gov. Accessed April 13, 2023. https://clinicaltrials.gov/ct2/show/NCT03886311?term=NCT03886311&draw=2&rank=1

68.

Study of nivolumab and Ipilimumab in children and young adults with INI1-negative cancers - full text view - ClinicalTrials.gov. Accessed April 13, 2023. https://clinicaltrials.gov/ct2/show/NCT04416568?term=NCT04416568&draw=2&rank=1

69.

Paoluzzi

Cacavio

Ghesani

, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6(1):24-27. doi:10.1186/s13569-016-0064-0

70.

Tawbi

Burgess

Bolejack

, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493-1501. doi:10.1016/S1470-2045(17)30624-1

71.

Papadopoulos

Romero

Gonzalez

Dix

Lowy

Fury

. Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncol. 2018;23(1):118-120. doi:10.1634/theoncologist.2017-0344

72.

A study of anlotinib combined with or without PD-1 antibody on unresectable high-grade chondrosarcoma - tabular view - ClinicalTrials.gov. Accessed April 14, 2023. https://clinicaltrials.gov/ct2/show/record/NCT05193188?term=NCT05193188&draw=2&rank=1

73.

Flucke

van Noesel

Siozopoulou

, et al. EWSR1—the most common rearranged gene in soft tissue lesions, which also occurs in different bone lesions: an updated review. Diagnostics. 2021;11(6):1093. doi:10.3390/DIAGNOSTICS11061093

74.

Morioka

Takahashi

Araki

, et al. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer. 2016;16(1):479. doi:10.1186/S12885-016-2511-Y

75.

Phase 1 study of INBRX-109 in subjects with locally advanced or metastatic solid tumors including sarcomas - full text view - ClinicalTrials.gov. Accessed April 14, 2023. https://clinicaltrials.gov/ct2/show/NCT03715933?term=NCT03715933&draw=2&rank=1

76.

Chawla

Wasp

Shepard

, et al. A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma. J Clin Oncol. 2022;40(16_suppl):TPS11582-TPS11582. doi:10.1200/JCO.2022.40.16_SUPPL.TPS11582

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB